Will We Have the Tools to Address a Reemergent Zika Virus Epidemic?
Authors: Ann Chahroudi, Sallie Permar
Journal: Annals of Internal Medicine (2021)

EditorialsMay 2021Will We Have the Tools to Address a Reemergent Zika Virus Epidemic?Ann Chahroudi, MD, PhD and Sallie Permar, MD, PhDAnn Chahroudi, MD, PhDEmory University School of Medicine and Children's Healthcare of Atlanta, Atlanta, GeorgiaSearch for more papers by this author and Sallie Permar, MD, PhDNewYork Presbyterian/Weill Cornell Medical School, New York, New YorkSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/M21-0397 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Zika virus (ZIKV) is a flavivirus transmitted by the bite of an Aedes genus mosquito, as well as from mother-to-fetus, during sexual intercourse, and through blood transfusions. Most commonly, infection is asymptomatic or mildly symptomatic. However, infection during pregnancy is associated with adverse fetal outcomes, including stillbirth, and birth defects, such as microcephaly and other brain anomalies, ocular abnormalities, congenital contractures, and increased muscle tone (1). Congenital ZIKV syndrome (CZS) presents a heavy burden to families and society. Moreover, other severe outcomes after ZIKV infection have been noted, including Guillain–Barré syndrome, encephalitis, and neurodevelopmental consequences for children infected postnatally (2, ...References1. Moore CA, Staples JE, Dobyns WB, et al. Characterizing the pattern of anomalies in congenital Zika syndrome for pediatric clinicians. JAMA Pediatr. 2017;171:288-95. [PMID: 27812690] doi:10.1001/jamapediatrics.2016.3982 CrossrefMedlineGoogle Scholar2. Lebov JF, Brown LM, MacDonald PDM, et al. Review: evidence of neurological sequelae in children with acquired Zika virus infection. Pediatr Neurol. 2018;85:16-20. [PMID: 30343688] doi:10.1016/j.pediatrneurol.2018.03.001 CrossrefMedlineGoogle Scholar3. Raper J, Chahroudi A. Clinical and preclinical evidence for adverse neurodevelopment after postnatal Zika virus infection. Trop Med Infect Dis. 2021;6. [PMID: 33445671] doi:10.3390/tropicalmed6010010 MedlineGoogle Scholar4. Salisch NC, Stephenson KE, Williams K, et al. A double-blind, randomized, placebo-controlled phase 1 study of Ad26.ZIKV.001, an Ad26-vectored anti–Zika virus vaccine. Ann Intern Med. 2021;174:585-594. doi:10.7326/M20-5306 Google Scholar5. Russell WA. Estimating the effect of discontinuing universal screening of donated blood for Zika virus in the 50 U.S. states. Ann Intern Med. 2021;174:728-730. doi:10.7326/M20-6879 Google Scholar6. Castanha PMS, Marques ETA. A glimmer of hope: recent updates and future challenges in Zika vaccine development. Viruses. 2020;12. [PMID: 33266129] doi:10.3390/v12121371 CrossrefMedlineGoogle Scholar7. Sadoff J, Le Gars, Shukarev G, et al. Interim results of a phase 1-2a trial of Ad26.COV2.S Covid-19 vaccine. N Engl J Med. 2021. [PMID: 33440088] doi:10.1056/NEJMoa2034201 CrossrefMedlineGoogle Scholar8. Buchbinder SP, Mehrotra DV, Duerr A, et al; Step Study Protocol Team. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet. 2008;372:1881-93. [PMID: 19012954] doi:10.1016/S0140-6736(08)61591-3 CrossrefMedlineGoogle Scholar9. Marchant A, Sadarangani M, Garand M, et al. Maternal immunisation: collaborating with mother nature. Lancet Infect Dis. 2017;17:e197-e208. [PMID: 28433705] doi:10.1016/S1473-3099(17)30229-3 CrossrefMedlineGoogle Scholar10. Ruchusatsawat K, Wongjaroen P, Posanacharoen A, et al. Long-term circulation of Zika virus in Thailand: an observational study. Lancet Infect Dis. 2019;19:439-46. [PMID: 30826189] doi:10.1016/S1473-3099(18)30718-7 CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: Emory University School of Medicine and Children's Healthcare of Atlanta, Atlanta, GeorgiaNewYork Presbyterian/Weill Cornell Medical School, New York, New YorkDisclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M21-0397.Corresponding Author: Sallie Permar, MD, PhD, Weill Cornell Medical School, 525 East 68th Street, New York, NY 10021; e-mail, [email protected]cornell.edu.Current Author Addresses: Dr. Chahroudi: Health Sciences Research Building, 1760 Haygood Drive, Atlanta, GA 30322.Dr. Permar: Weill Cornell Medical School, 525 East 68th Street, New York, NY 10021.This article was published at Annals.org on 16 February 2021. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoA Double-Blind, Randomized, Placebo-Controlled Phase 1 Study of Ad26.ZIKV.001, an Ad26-Vectored Anti–Zika Virus Vaccine Nadine C. Salisch , Kathryn E. Stephenson , Kristi Williams , Freek Cox , Leslie van der Fits , Dirk Heerwegh , Carla Truyers , Marrit N. Habets , Diane G. Kanjilal , Rafael A. Larocca , Peter Abbink , Jinyan Liu , Lauren Peter , Carlos Fierro , Rafael A. De La Barrera , Kayvon Modjarrad , Roland C. Zahn , Jenny Hendriks , Conor P. Cahill , Maarten Leyssen , Macaya Douoguih , Johan van Hoof , Hanneke Schuitemaker , and Dan H. Barouch Estimating the Effect of Discontinuing Universal Screening of Donated Blood for Zika Virus in the 50 U.S. States W. Alton Russell Estimating the Effect of Discontinuing Universal Screening of Donated Blood for Zika Virus in the 50 U.S. States W. Alton Russell Metrics May 2021Volume 174, Issue 5Page: 708-709KeywordsBloodBlood transfusionCOVID-19Eye diseasesImmunityPopulation statisticsPregnancyVaccinesViral diseasesZika virus ePublished: 16 February 2021 Issue Published: May 2021 Copyright & PermissionsCopyright © 2021 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...